Завершено
Фаза II
Россия
TMC207; Placebo; Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) · Janssen Infectious Diseases BVBA
A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).